Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase III
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Hyaluronidase (Primary) ; Gemcitabine; Paclitaxel; Rivaroxaban
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Mar 2018 Planned number of patients changed from 56 to 88.
- 20 Jan 2018 Updated safety and efficacy data will be reported in future.
- 20 Jan 2018 Interim results (n=28) assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium